Literature DB >> 23636966

Significance of I-123 metaiodobenzylguanidine (¹²³I-MIBG) lung activity in subjects with heart failure in comparison to healthy control subjects.

Myron C Gerson1, Alok K Dwivedi, Mouhamad Abdallah, Rakesh Shukla, Arnold F Jacobson.   

Abstract

BACKGROUND: Little is known concerning the significance of lung activity of the sympathetic neuronal imaging agent (123)I-MIBG in heart failure patients and healthy subjects.
METHODS: (123)I-MIBG activity was assessed in lung, heart, and mediastinum regions of interest on early and late planar images in 951 heart failure patients and 94 controls. Cox regression analyses were performed to identify factors associated with outcome events during a median 17 month follow-up.
RESULTS: Heart failure subjects with pulmonary disease had significantly reduced late lung-to-mediastinum (L/M) ratios compared to heart failure subjects without pulmonary disease. Late L/M ratio was greater in heart failure subjects without outcome events than either subjects with events or healthy controls. L/M ratio was an independent predictor of all-cause mortality. Subjects with combined favorable prognosis L/M ratio ≥ 1.7 and heart-to-mediastinum ratio (H/M) ≥ 1.6 had a significantly lower 2-year mortality (2.0%) than subjects with unfavorable L/M ratio < 1.7 and H/M ratio < 1.6 (17.7% 2-year mortality, P < .0008).
CONCLUSIONS: Increased (123)I-MIBG lung activity in heart failure subjects, compared to controls, is associated with a relatively low risk of adverse events, including all-cause mortality. L/M ratio may, therefore, be useful to provide incremental prognostic information on (123)I-MIBG imaging.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636966     DOI: 10.1007/s12350-013-9714-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  14 in total

1.  Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine.

Authors:  Myron C Gerson; Laura L Craft; Nancy McGuire; Damodhar P Suresh; William T Abraham; Lynne E Wagoner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Increased lung uptake of thallium-201 during exercise myocardial imaging: clinical, hemodynamic and angiographic implications in patients with coronary artery disease.

Authors:  C A Boucher; L M Zir; G A Beller; R D Okada; K A McKusick; H W Strauss; G M Pohost
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

3.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.

Authors:  Arnold F Jacobson; Roxy Senior; Manuel D Cerqueira; Nathan D Wong; Gregory S Thomas; Victor A Lopez; Denis Agostini; Fred Weiland; Harish Chandna; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2010-02-25       Impact factor: 24.094

4.  131I-metaiodobenzylguanidine uptake in the isolated rat lung: a potential marker of endothelial cell function.

Authors:  D O Slosman; D Davidson; A B Brill; P O Alderson
Journal:  Eur J Nucl Med       Date:  1988

5.  Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors.

Authors:  N Yamaguchi; J de Champlain; R A Nadeau
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

6.  Risk stratification assessed by combined lung and heart iodine-123 metaiodobenzylguanidine uptake in patients with idiopathic dilated cardiomyopathy.

Authors:  Yuichi Kamiyoshi; Yoshikazu Yazaki; Kazutoshi Urushibata; Tomonori Koizumu; Hiroki Kasai; Atsushi Izawa; Osamu Kinoshita; Minoru Hongo; Uichi Ikeda
Journal:  Am J Cardiol       Date:  2008-03-26       Impact factor: 2.778

7.  Characteristics and regulation of 123I-MIBG transport in cultured pulmonary endothelial cells.

Authors:  Kyung-Han Lee; Bong-Ho Ko; Jin-Young Paik; Kyung-Ho Jung; Jun-Sang Bae; Joon-Young Choi; Yearn Seong Choe; Byung-Tae Kim
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

8.  In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of (123)I-metaiodobenzylguanidine.

Authors:  Tsuyoshi Arao; Noriaki Takabatake; Makoto Sata; Shuichi Abe; Yoko Shibata; Tsuguo Honma; Kazuei Takahashi; Akio Okada; Yasuchika Takeishi; Isao Kubota
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

9.  Identification of presynaptic beta 2-adrenoceptors on the sympathetic nerve fibres of the human pulmonary artery.

Authors:  M Göthert; F Hentrich
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

10.  Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ( (123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout.

Authors:  Hein J Verberne; G Aernout Somsen; Pavol Povinec; Berthe L F van Eck-Smit; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

View more
  4 in total

Review 1.  SPECT and PET in ischemic heart failure.

Authors:  George Angelidis; Gregory Giamouzis; Georgios Karagiannis; Javed Butler; Ioannis Tsougos; Varvara Valotassiou; George Giannakoulas; Nikolaos Dimakopoulos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis; Panagiotis Georgoulias
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

2.  Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease.

Authors:  Jin-Kyoung Oh; Eun-Kyoung Choi; In-Uk Song; Joong-Seok Kim; Yong-An Chung
Journal:  J Neural Transm (Vienna)       Date:  2015-05-24       Impact factor: 3.575

3.  I-123 MIBG Cardiac Imaging.

Authors:  Prem Soman; Mark I Travin; Myron Gerson; S James Cullom; Randall Thompson
Journal:  J Nucl Cardiol       Date:  2015-04-01       Impact factor: 5.952

4.  123I-mIBG: Simplicity and reproducibility.

Authors:  Kevin Curl; Christopher L Hansen
Journal:  J Nucl Cardiol       Date:  2018-01-29       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.